Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC5A2 | P31639 | 6/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3191462 | 1.00 | SLC5A2 (0.50) | SLC5A2CYP2C19CYP3A4CYP2D6MAPT | |
| SCHEMBL9475305 | 1.00 | SLC5A2 (0.50) | SLC5A2CYP2C19CYP3A4CYP2D6MAPT | |
| SCHEMBL9486651 | 1.00 | SLC5A2 (0.50) | SLC5A2CYP2C19CYP3A4CYP2D6MAPT | |
| SCHEMBL1535687 | 1.00 | SLC5A2 (0.50) | SLC5A2CYP2C19CYP3A4CYP2D6MAPT | |
| SCHEMBL9475300 | 1.00 | SLC5A2 (0.50) | SLC5A2CYP2C19CYP3A4CYP2D6MAPT | |
| SCHEMBL9486645 | 1.00 | SLC5A2 (0.50) | SLC5A2CYP2C19CYP3A4CYP2D6MAPT | |
| SCHEMBL9543216 | 1.00 | SLC5A2 (0.50) | SLC5A2CYP2C19CYP3A4CYP2D6MAPT | |
| SCHEMBL9543039 | 1.00 | SLC5A2 (0.50) | SLC5A2CYP2C19CYP3A4CYP2D6MAPT | |
| SCHEMBL4139162 | 0.83 | SLC5A2 (0.71) | SLC5A2 | |
| SCHEMBL20529512 | 0.83 | SLC5A2 (0.71) | SLC5A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 100 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2056445-A | — | — | None | — | — | JP | disclosed |
| US-11043336-B2 | Actinic and electron beam radiation curable water based electrode binders and electrodes incorporating same | MILTEC CORPORATION (US) | 2021-06-22 | — | — | US | disclosed |
| US-10544133-B2 | Heteroaryl substituted pyridyl compounds useful as kinase modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-01-28 | — | — | US | disclosed |
| EP-2997612-B1 | ACTINIC AND ELECTRON BEAM RADIATION CURABLE WATER BASED ELECTRODE BINDERS AND ELECTRODES INCORPORATING SAME | MILTEC CORP (US) | 2019-11-20 | — | — | EP | disclosed |
| US-20190019631-A1 | Actinic and Electron Beam Radiation Curable Water Based Electrode Binders and Electrodes Incorporating Same | MILTEC CORPORATION | 2019-01-17 | — | — | US | disclosed |
| US-20180370956-A1 | HETEROARYL SUBSTITUTED PYRIDYL COMPOUNDS USEFUL AS KINASE MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2018-12-27 | — | — | US | disclosed |
| US-10102979-B2 | Actinic and electron beam radiation curable water based electrode binders and electrodes incorporating same | MILTEC CORPORATION (US) | 2018-10-16 | — | — | US | disclosed |
| US-10023562-B2 | Heteroaryl substituted pyridyl compounds useful as kinase modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-07-17 | — | — | US | disclosed |
| US-20170210730-A1 | HETEROARYL SUBSTITUTED PYRIDYL COMPOUNDS USEFUL AS KINASE MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2017-07-27 | — | — | US | disclosed |
| US-9657009-B2 | Heteroaryl substituted pyridyl compounds useful as kinase modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-05-23 | — | — | US | disclosed |
| WO-2000048593-A1 | EPOXIDE HYDROLASE COMPLEXES AND METHODS THEREWITH | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2000-08-24 | — | — | WO | disclosed |
| US-5391735-A | Process for the preparation of 3-substituted derivatives of 1-amino-2-hydroxy-propane | FARMITALIA CARLO ERBA S.P.A. (IT) | 1995-02-21 | — | — | US | disclosed |
| US-5250572-A | Treating depression | ELI LILLY AND COMPANY (US) | 1993-10-05 | — | — | US | disclosed |
| EP-0301401-B1 | LEUKOTRIENE ANTAGONISTS, PROCESS FOR THEIR PREPARATION, THEIR USE IN THE TREATMENT OF ILLNESSES | HOECHST AKTIENGESELLSCHAFT (DE) | 1991-11-27 | — | — | EP | disclosed |
| US-5068433-A | Antidepressants | FARMITALIA CARLO ERBA, S.R.L. (IT) | 1991-11-26 | — | — | US | disclosed |
| US-4937331-A | Chemical intermediates for antibiotics | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 1990-06-26 | — | — | US | disclosed |
| JP-H0256445-A | PRODUCTION OF (R)-ALPHA-METHOXYPHENYLACETIC ACID | TOOA EIYOO KK | 1990-02-26 | — | — | JP | disclosed |
| EP-0334593-A1 | Chiral azetidinone epoxides | THE PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 1989-09-27 | — | — | EP | disclosed |
| US-4851440-A | ASTHMA | HOECHST AKTIENGESELLSCHAFT (DE) | 1989-07-25 | — | — | US | disclosed |
| EP-0301401-A2 | Leukotriene antagonists, process for their preparation, their use in the treatment of illnesses | HOECHST AKTIENGESELLSCHAFT (DE) | 1989-02-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10544133-B2 | Heteroaryl substituted pyridyl compounds useful as kinase modulators | IRAK4, IRAK3, IRAK2 | SLC5A2 4393/4885CYP2C19 3316/4885CYP3A4 1228/4885 |
| US-10023562-B2 | Heteroaryl substituted pyridyl compounds useful as kinase modulators | IRAK4, IRAK3, IRAK2 | SLC5A2 4393/4885CYP2C19 3316/4885CYP3A4 1228/4885 |
| US-20180370956-A1 | HETEROARYL SUBSTITUTED PYRIDYL COMPOUNDS USEFUL AS KINASE MODULATORS | IRAK4, IRAK3, IRAK2 | SLC5A2 4393/4885CYP2C19 3316/4885CYP3A4 1228/4885 |
| US-20170210730-A1 | HETEROARYL SUBSTITUTED PYRIDYL COMPOUNDS USEFUL AS KINASE MODULATORS | IRAK4, IRAK3, IRAK2 | SLC5A2 4393/4885CYP2C19 3316/4885CYP3A4 1228/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.